Harnessing tumor necrosis factor receptors to enhance antitumor activities of drugs

Chemical Research in Toxicology

Volumn 24, Issue 10, 2011, Pages 1610-1616

  Muntané, Jordi ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BORTEZOMIB; CYCLOHEXIMIDE; DEATH RECEPTOR 3; DEATH RECEPTOR 4; DEATH RECEPTOR 5; ECTODYSPLASIN RECEPTOR; EDAR RECEPTOR; FAS LIGAND; GOLIMUMAB; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; MACROGOL; NERVE GROWTH FACTOR RECEPTOR; R 125224; SEPRASE; THALIDOMIDE; TRAIL RECEPTOR DR6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B LYMPHOCYTE; CANCER CELL; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL PROLIFERATION; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; LYMPHOCYTE PROLIFERATION; MYELOMA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; RECEPTORS, DEATH DOMAIN; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 80054757912     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx2002349     Document Type: Review

References (109)

1. Ricciardi, S., Tomao, S., and de Marinis, F. (2009) Toxicity of targeted therapy in non-small-cell lung cancer management Clin. Lung Cancer 10, 28-35
2. Fojo, T. and Parkinson, D. R. (2010) Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin. Cancer Res. 16, 5972-5980
3. Zhivotovsky, B. and Kroemer, G. (2004) Apoptosis and genomic instability Nat. Rev. Mol. Cell Biol. 5, 752-762 (Pubitemid 39208184)
4. Bhardwaj, A. and Aggarwal, B. B. (2003) Receptor-mediated choreography of life and death J. Clin. Immunol. 23, 317-332 (Pubitemid 37083187)
5. Naismith, J. H. and Sprang, S. R. (1998) Modularity in the TNF-receptor family Trends Biochem. Sci. 23, 74-79 (Pubitemid 28085231)
6. Bodmer, J. L., Schneider, P., and Tschopp, J. (2002) The molecular architecture of the TNF superfamily Trends Biochem. Sci. 27, 19-26 (Pubitemid 34131621)
7. Fulda, S. and Debatin, K. M. (2004) Exploiting death receptor signaling pathways for tumor therapy Biochim. Biophys. Acta 1705, 27-41 (Pubitemid 39592904)
8. Ashkenazi, A. and Dixit, V. M. (1998) Death receptors: signaling and modulation Science 281, 1305-1308 (Pubitemid 28406815)
9. Lavrik, I., Golks, A., and Krammer, P. H. (2005) Death receptor signaling J. Cell Sci. 118, 265-267 (Pubitemid 40277339)
10. Peter, M. E. and Krammer, P. H. (2003) The CD95(APO-1/Fas) DISC and beyond Cell Death Differ. 10, 26-35 (Pubitemid 36511830)
11. Locksley, R. M., Killeen, N., and Lenardo, M. J. (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology Cell 104, 487-501 (Pubitemid 32201945)
12. Feldmann, M., Brennan, F. M., Paleolog, E., Cope, A., Taylor, P., Williams, R., Woody, J., and Maini, R. N. (2004) Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Novartis Found. Symp., 256, 53-69, discussion 69-73, 106-111, 266-109.
13. Komori, A., Yatsunami, J., Suganuma, M., Okabe, S., Abe, S., Sakai, A., Sasaki, K., and Fujiki, H. (1993) Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation Cancer Res. 53, 1982-1985 (Pubitemid 23145713)
14. Chen, G. and Goeddel, D. V. (2002) TNF-R1 signaling: a beautiful pathway Science 296, 1634-1635 (Pubitemid 34579145)
15. Micheau, O. and Tschopp, J. (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes Cell 114, 181-190 (Pubitemid 36936912)
16. Seitz, S. J., Schleithoff, E. S., Koch, A., Schuster, A., Teufel, A., Staib, F., Stremmel, W., Melino, G., Krammer, P. H., Schilling, T., and Muller, M. (2010) Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway Int. J. Cancer 126, 2049-2066
17. Gressner, O., Schilling, T., Lorenz, K., Schulze Schleithoff, E., Koch, A., Schulze-Bergkamen, H., Lena, A. M., Candi, E., Terrinoni, A., Catani, M. V., Oren, M., Melino, G., Krammer, P. H., Stremmel, W., and Muller, M. (2005) TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria EMBO J. 24, 2458-2471 (Pubitemid 41032596)
18. Muller, M., Schilling, T., Sayan, A. E., Kairat, A., Lorenz, K., Schulze-Bergkamen, H., Oren, M., Koch, A., Tannapfel, A., Stremmel, W., Melino, G., and Krammer, P. H. (2005) TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma Cell Death Differ. 12, 1564-1577 (Pubitemid 41679162)
19. Shibata, H., Yoshioka, Y., Ikemizu, S., Kobayashi, K., Yamamoto, Y., Mukai, Y., Okamoto, T., Taniai, M., Kawamura, M., Abe, Y., Nakagawa, S., Hayakawa, T., Nagata, S., Yamagata, Y., Mayumi, T., Kamada, H., and Tsutsumi, Y. (2004) Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window Clin. Cancer Res. 10, 8293-8300 (Pubitemid 40053389)
20. Russo, M., Mupo, A., Spagnuolo, C., and Russo, G. L. (2010) Exploring death receptor pathways as selective targets in cancer therapy Biochem. Pharmacol. 80, 674-682
21. Gerspach, J., Pfizenmaier, K., and Wajant, H. (2009) Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects Biofactors 35, 364-372
22. Weichselbaum, R. R. and Kufe, D. (2009) Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers Cancer Gene Ther. 16, 609-619
23. Wang, C. Y., Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB Nat. Med. 5, 412-417 (Pubitemid 29180579)
24. Lee, K. Y., Chang, W., Qiu, D., Kao, P. N., and Rosen, G. D. (1999) PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells J. Biol. Chem. 274, 13451-13455
25. Orlowski, R. Z. and Baldwin, A. S., Jr. (2002) NF-kappaB as a therapeutic target in cancer Trends Mol. Med. 8, 385-389
26. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D. L., Kauffman, M., Adams, J., Schenkein, D. P., and Anderson, K. C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma N. Engl. J. Med. 348, 2609-2617 (Pubitemid 36741588)
27. Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., and Tak, P. P. (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol. Ther. 117, 244-279
28. Mitoma, H., Horiuchi, T., Tsukamoto, H., Tamimoto, Y., Kimoto, Y., Uchino, A., To, K., Harashima, S., Hatta, N., and Harada, M. (2008) Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab Arthritis Rheum. 58, 1248-1257 (Pubitemid 351705913)
29. Shen, C., Van Assche, G., Rutgeerts, P., and Ceuppens, J. L. (2006) Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model Inflamm. Bowel Dis. 12, 22-28 (Pubitemid 43032447)
30. Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., and Montori, V. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295, 2275-2285 (Pubitemid 43736578)
31. Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., and Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation J. Exp. Med. 177, 1675-1680 (Pubitemid 23146134)
32. Kumar, S., Witzig, T. E., and Rajkumar, S. V. (2002) Thalidomide as an anti-cancer agent J. Cell. Mol. Med. 6, 160-174 (Pubitemid 44133967)
33. Sprick, M. R., Rieser, E., Stahl, H., Grosse-Wilde, A., Weigand, M. A., and Walczak, H. (2002) Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8 EMBO J. 21, 4520-4530 (Pubitemid 34984339)
34. Golks, A., Brenner, D., Fritsch, C., Krammer, P. H., and Lavrik, I. N. (2005) c-FLIPR, a new regulator of death receptor-induced apoptosis J. Biol. Chem. 280, 14507-14513 (Pubitemid 40562792)
35. Lavrik, I., Krueger, A., Schmitz, I., Baumann, S., Weyd, H., Krammer, P. H., and Kirchhoff, S. (2003) The active caspase-8 heterotetramer is formed at the CD95 DISC Cell Death Differ. 10, 144-145 (Pubitemid 36511841)
36. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J. L., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., and Tschopp, J. (1997) Inhibition of death receptor signals by cellular FLIP Nature 388, 190-195 (Pubitemid 27297457)
37. Kreuz, S., Siegmund, D., Rumpf, J. J., Samel, D., Leverkus, M., Janssen, O., Hacker, G., Dittrich-Breiholz, O., Kracht, M., Scheurich, P., and Wajant, H. (2004) NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP J. Cell Biol. 166, 369-380 (Pubitemid 39031240)
38. Peter, M. E., Legembre, P., and Barnhart, B. C. (2005) Does CD95 have tumor promoting activities? Biochim. Biophys. Acta 1755, 25-36 (Pubitemid 40720239)
39. Peter, M. E., Budd, R. C., Desbarats, J., Hedrick, S. M., Hueber, A. O., Newell, M. K., Owen, L. B., Pope, R. M., Tschopp, J., Wajant, H., Wallach, D., Wiltrout, R. H., Zornig, M., and Lynch, D. H. (2007) The CD95 receptor: apoptosis revisited Cell 129, 447-450 (Pubitemid 46660984)
40. Chen, L., Park, S. M., Tumanov, A. V., Hau, A., Sawada, K., Feig, C., Turner, J. R., Fu, Y. X., Romero, I. L., Lengyel, E., and Peter, M. E. (2010) CD95 promotes tumour growth Nature 465, 492-496
41. Ruiz-Ruiz, M. C. and Lopez-Rivas, A. (1999) p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells Cell Death Differ. 6, 271-280 (Pubitemid 29145831)
42. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. (1996) Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells Nat. Med. 2, 574-577 (Pubitemid 26150685)
43. Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53 J. Clin. Invest. 99, 403-413 (Pubitemid 27414797)
44. Herr, I., Wilhelm, D., Bohler, T., Angel, P., and Debatin, K. M. (1997) Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis EMBO J. 16, 6200-6208 (Pubitemid 27458340)
45. Muller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., and Krammer, P. H. (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs J. Exp. Med. 188, 2033-2045 (Pubitemid 28562520)
46. Kavurma, M. M. and Khachigian, L. M. (2003) Signaling and transcriptional control of Fas ligand gene expression Cell Death Differ. 10, 36-44 (Pubitemid 36511831)
47. Fukazawa, T., Fujiwara, T., Morimoto, Y., Shao, J., Nishizaki, M., Kadowaki, Y., Hizuta, A., Owen-Schaub, L. B., Roth, J. A., and Tanaka, N. (1999) Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells Oncogene 18, 2189-2199 (Pubitemid 29186920)
48. Medema, J. P., de Jong, J., van Hall, T., Melief, C. J., and Offringa, R. (1999) Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein J. Exp. Med. 190, 1033-1038 (Pubitemid 29480832)
49. Micheau, O. (2003) Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin. Ther. Targets 7, 559-573 (Pubitemid 37063342)
50. Nakayama, J., Ogawa, Y., Yoshigae, Y., Onozawa, Y., Yonemura, A., Saito, M., Ichikawa, K., Yamoto, T., Komai, T., Tatsuta, T., and Ohtsuki, M. (2006) A humanized anti-human Fas antibody, R-125224, induces apoptosis in type I activated lymphocytes but not in type II cells Int. Immunol. 18, 113-124 (Pubitemid 43057042)
51. Rubinchik, S., Wang, D., Yu, H., Fan, F., Luo, M., Norris, J. S., and Dong, J. Y. (2001) A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression Mol. Ther. 4, 416-426 (Pubitemid 33100279)
52. Kodaira, H., Kume, A., Ogasawara, Y., Urabe, M., Kitano, K., Kakizuka, A., and Ozawa, K. (1998) Fas and mutant estrogen receptor chimeric gene: a novel suicide vector for tamoxifen-inducible apoptosis Jpn. J. Cancer Res. 89, 741-747 (Pubitemid 28401160)
53. Aoki, K., Kurooka, M., Chen, J. J., Petryniak, J., Nabel, E. G., and Nabel, G. J. (2001) Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity Nat. Immunol. 2, 333-337 (Pubitemid 33706344)
54. Papenfuss, K., Cordier, S. M., and Walczak, H. (2008) Death receptors as targets for anti-cancer therapy J. Cell. Mol. Med. 12, 2566-2585
55. Liu, Z., Liu, R., Qiu, J., Yin, P., Luo, F., Su, J., Li, W., Chen, C., Fan, X., Zhang, J., and Zhuang, G. (2009) Combination of human Fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response Cell. Mol. Immunol. 6, 167-174
56. Marsters, S. A., Sheridan, J. P., Donahue, C. J., Pitti, R. M., Gray, C. L., Goddard, A. D., Bauer, K. D., and Ashkenazi, A. (1996) Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B Curr. Biol. 6, 1669-1676 (Pubitemid 27050235)
57. Tan, K. B., Harrop, J., Reddy, M., Young, P., Terrett, J., Emery, J., Moore, G., and Truneh, A. (1997) Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells Gene 204, 35-46 (Pubitemid 28022168)
58. Migone, T. S., Zhang, J., Luo, X., Zhuang, L., Chen, C., Hu, B., Hong, J. S., Perry, J. W., Chen, S. F., Zhou, J. X., Cho, Y. H., Ullrich, S., Kanakaraj, P., Carrell, J., Boyd, E., Olsen, H. S., Hu, G., Pukac, L., Liu, D., Ni, J., Kim, S., Gentz, R., Feng, P., Moore, P. A., Ruben, S. M., and Wei, P. (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator Immunity 16, 479-492 (Pubitemid 34260924)
59. Al-Lamki, R. S., Wang, J., Thiru, S., Pritchard, N. R., Bradley, J. A., Pober, J. S., and Bradley, J. R. (2003) Expression of silencer of death domains and death-receptor-3 in normal human kidney and in rejecting renal transplants Am. J. Pathol. 163, 401-411 (Pubitemid 36909404)
60. Ringel, B., Ibrahim, S. M., Kohler, H., Ringel, J., Koczan, D., Liebe, S., Lohr, M., and Thiesen, H. J. (1999) Apoptotic molecules in pancreatic carcinoma cell lines Ann. N.Y. Acad. Sci. 880, 175-178 (Pubitemid 29349125)
61. Bodmer, J. L., Burns, K., Schneider, P., Hofmann, K., Steiner, V., Thome, M., Bornand, T., Hahne, M., Schroter, M., Becker, K., Wilson, A., French, L. E., Browning, J. L., MacDonald, H. R., and Tschopp, J. (1997) TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95) Immunity 6, 79-88 (Pubitemid 27130217)
62. Chinnaiyan, A. M., O'Rourke, K., Yu, G. L., Lyons, R. H., Garg, M., Duan, D. R., Xing, L., Gentz, R., Ni, J., and Dixit, V. M. (1996) Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95 Science 274, 990-992 (Pubitemid 26398422)
63. Yang, C. R., Hsieh, S. L., Teng, C. M., Ho, F. M., Su, W. L., and Lin, W. W. (2004) Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action Cancer Res. 64, 1122-1129
64. Wen, L., Zhuang, L., Luo, X., and Wei, P. (2003) TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells J. Biol. Chem. 278, 39251-39258 (Pubitemid 37221829)
65. Wang, E. C., Thern, A., Denzel, A., Kitson, J., Farrow, S. N., and Owen, M. J. (2001) DR3 regulates negative selection during thymocyte development Mol. Cell. Biol. 21, 3451-3461 (Pubitemid 32381781)
66. Meylan, F., Davidson, T. S., Kahle, E., Kinder, M., Acharya, K., Jankovic, D., Bundoc, V., Hodges, M., Shevach, E. M., Keane-Myers, A., Wang, E. C., and Siegel, R. M. (2008) The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases Immunity 29, 79-89
67. Murtaza, I., Adhami, V. M., Hafeez, B. B., Saleem, M., and Mukhtar, H. (2009) Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB Int. J. Cancer 125, 2465-2473
68. Zhang, L., Zhang, Y., Yang, X., and Lv, Z. (2009) Lupeol, a dietary triterpene, inhibited growth, and induced apoptosis through down-regulation of DR3 in SMMC7721 cells Cancer Invest. 27, 163-170
69. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and Goodwin, R. G. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3, 673-682 (Pubitemid 26091143)
70. Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., Deforge, L., Pai, R., Hymowitz, S. G., and Ashkenazi, A. (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling J. Biol. Chem. 280, 2205-2212
71. MacFarlane, M., Inoue, S., Kohlhaas, S. L., Majid, A., Harper, N., Kennedy, D. B., Dyer, M. J., and Cohen, G. M. (2005) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1 Cell Death Differ. 12, 773-782 (Pubitemid 40945984)
72. Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., and Ashkenazi, A. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5 Immunity 12, 611-620
73. Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., and Walczak, H. (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2 Immunity 12, 599-609
74. Johnstone, R. W., Frew, A. J., and Smyth, M. J. (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy Nat. Rev. Cancer 8, 782-798
75. Liu, X., Yue, P., Khuri, F. R., and Sun, S. Y. (2004) p53 upregulates death receptor 4 expression through an intronic p53 binding site Cancer Res. 64, 5078-5083 (Pubitemid 39006522)
76. Kelley, S. K., Harris, L. A., Xie, D., Deforge, L., Totpal, K., Bussiere, J., and Fox, J. A. (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety J. Pharmacol. Exp. Ther. 299, 31-38 (Pubitemid 32905115)
77. Holoch, P. A. and Griffith, T. S. (2009) TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies Eur. J. Pharmacol. 625, 63-72
78. Griffith, T. S., Anderson, R. D., Davidson, B. L., Williams, R. D., and Ratliff, T. L. (2000) Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis J. Immunol. 165, 2886-2894 (Pubitemid 30660741)
79. Griffith, T. S. and Broghammer, E. L. (2001) Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus Mol. Ther. 4, 257-266 (Pubitemid 32851290)
80. Luster, T. A., Carrell, J. A., McCormick, K., Sun, D., and Humphreys, R. (2009) Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib Mol. Cancer Ther. 8, 292-302
81. Brooks, A. D., Ramirez, T., Toh, U., Onksen, J., Elliott, P. J., Murphy, W. J., and Sayers, T. J. (2005) The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis Ann. N.Y. Acad. Sci. 1059, 160-167 (Pubitemid 43211618)
82. Rosato, R. R., Almenara, J. A., Coe, S., and Grant, S. (2007) The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation Cancer Res. 67, 9490-9500 (Pubitemid 47535939)
83. Fulda, S. and Debatin, K. M. (2005) HDAC inhibitors: double edge sword for TRAIL cancer therapy? Cancer Biol. Ther. 4, 1113-1115 (Pubitemid 41598566)
84. Ray, S., Bucur, O., and Almasan, A. (2005) Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor Apoptosis 10, 1411-1418 (Pubitemid 43117685)
85. Herbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O'Dwyer, P. J., Gordon, M. S., Novotny, W., Goldwasser, M. A., Tohnya, T. M., Lum, B. L., Ashkenazi, A., Jubb, A. M., and Mendelson, D. S. (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer J. Clin. Oncol. 28, 2839-2846
86. Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., Halpern, W., Corey, A., and Cohen, R. B. (2007) Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 J. Clin. Oncol. 25, 1390-1395 (Pubitemid 46706887)
87. Leong, S., Cohen, R. B., Gustafson, D. L., Langer, C. J., Camidge, D. R., Padavic, K., Gore, L., Smith, M., Chow, L. Q., von Mehren, M., O'Bryant, C., Hariharan, S., Diab, S., Fox, N. L., Miceli, R., and Eckhardt, S. G. (2009) Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study J. Clin. Oncol. 27, 4413-4421
88. Camidge, D. R. (2008) Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors Expert Opin. Biol. Ther. 8, 1167-1176
89. Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., Miceli, R., Ullrich, S. J., Fisher, G. A., and Tolcher, A. W. (2010) Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors Ann. Oncol. 21, 376-381
90. Pan, G., Bauer, J. H., Haridas, V., Wang, S., Liu, D., Yu, G., Vincenz, C., Aggarwal, B. B., Ni, J., and Dixit, V. M. (1998) Identification and functional characterization of DR6, a novel death domain-containing TNF receptor FEBS Lett. 431, 351-356 (Pubitemid 28352389)
91. Kasof, G. M., Lu, J. J., Liu, D., Speer, B., Mongan, K. N., Gomes, B. C., and Lorenzi, M. V. (2001) Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB Oncogene 20, 7965-7975 (Pubitemid 34001557)
92. Kitson, J., Raven, T., Jiang, Y. P., Goeddel, D. V., Giles, K. M., Pun, K. T., Grinham, C. J., Brown, R., and Farrow, S. N. (1996) A death-domain-containing receptor that mediates apoptosis Nature 384, 372-375 (Pubitemid 26408521)
93. Zhao, H., Yan, M., Wang, H., Erickson, S., Grewal, I. S., and Dixit, V. M. (2001) Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice J. Exp. Med. 194, 1441-1448 (Pubitemid 33081519)
94. Schmidt, C. S., Liu, J., Zhang, T., Song, H. Y., Sandusky, G., Mintze, K., Benschop, R. J., Glasebrook, A., Yang, D. D., and Na, S. (2003) Enhanced B cell expansion, survival, and humoral responses by targeting death receptor 6 J. Exp. Med. 197, 51-62 (Pubitemid 36110257)
95. Mikkola, M. L. and Thesleff, I. (2003) Ectodysplasin signaling in development Cytokine Growth Factor Rev. 14, 211-224 (Pubitemid 36693142)
96. Punj, V., Matta, H., and Chaudhary, P. M. (2010) X-linked ectodermal dysplasia receptor is downregulated in breast cancer via promoter methylation Clin. Cancer Res. 16, 1140-1148
97. Sinha, S. K. and Chaudhary, P. M. (2004) Induction of apoptosis by X-linked ectodermal dysplasia receptor via a caspase 8-dependent mechanism J. Biol. Chem. 279, 41873-41881 (Pubitemid 39313636)
98. Tanikawa, C., Ri, C., Kumar, V., Nakamura, Y., and Matsuda, K. (2010) Crosstalk of EDA-A2/XEDAR in the p53 signaling pathway Mol. Cancer Res. 8, 855-863
99. Brosh, R., Sarig, R., Natan, E. B., Molchadsky, A., Madar, S., Bornstein, C., Buganim, Y., Shapira, T., Goldfinger, N., Paus, R., and Rotter, V. (2010) p53-dependent transcriptional regulation of EDA2R and its involvement in chemotherapy-induced hair loss FEBS Lett. 584, 2473-2477
100. Rabizadeh, S. and Bredesen, D. E. (2003) Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR) Cytokine Growth Factor Rev. 14, 225-239 (Pubitemid 36693143)
101. Wheeler, E. F., Gong, H., Grimes, R., Benoit, D., and Vazquez, L. (1998) p75NTR and Trk receptors are expressed in reciprocal patterns in a wide variety of non-neural tissues during rat embryonic development, indicating independent receptor functions J. Comp. Neurol. 391, 407-428 (Pubitemid 28135644)
102. Roux, P. P. and Barker, P. A. (2002) Neurotrophin signaling through the p75 neurotrophin receptor Prog. Neurobiol. 67, 203-233
103. Djakiew, D., Pflug, B. R., Delsite, R., Onoda, M., Lynch, J. H., Arand, G., and Thompson, E. W. (1993) Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein Cancer Res. 53, 1416-1420 (Pubitemid 23097126)
104. Barbacid, M. (1994) The Trk family of neurotrophin receptors J. Neurobiol. 25, 1386-1403 (Pubitemid 24325064)
105. Miknyoczki, S. J., Wan, W., Chang, H., Dobrzanski, P., Ruggeri, B. A., Dionne, C. A., and Buchkovich, K. (2002) The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice Clin. Cancer Res. 8, 1924-1931 (Pubitemid 34633755)
106. Weeraratna, A. T., Dalrymple, S. L., Lamb, J. C., Denmeade, S. R., Miknyoczki, S., Dionne, C. A., and Isaacs, J. T. (2001) Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells Clin. Cancer Res. 7, 2237-2245 (Pubitemid 32751620)
107. Dionne, C. A., Camoratto, A. M., Jani, J. P., Emerson, E., Neff, N., Vaught, J. L., Murakata, C., Djakiew, D., Lamb, J., Bova, S., George, D., and Isaacs, J. T. (1998) Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587) Clin. Cancer Res. 4, 1887-1898 (Pubitemid 28369172)
108. Jin, H., Pan, Y., Zhao, L., Zhai, H., Li, X., Sun, L., He, L., Chen, Y., Hong, L., Du, Y., and Fan, D. (2007) p75 neurotrophin receptor suppresses the proliferation of human gastric cancer cells Neoplasia 9, 471-478 (Pubitemid 46983449)
109. Vanhecke, E., Adriaenssens, E., Verbeke, S., Meignan, S., Germain, E., Berteaux, N., Nurcombe, V., Le Bourhis, X., and Hondermarck, H. (2011) Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival Clin. Cancer Res. 17, 1741-1752